Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 511

TitleReference numberPublishedLast updated
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)TA1144
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessmentHTG776
Fetal monitoring in labourNG229
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1140
Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHST35
Hypertension in adults: diagnosis and managementNG136
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1137
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)TA1135
Type 2 diabetes in adults: managementNG28
Type 2 diabetes in adultsQS209
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)TA1132
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TA1124
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)TA1123
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
VA ECMO for postcardiotomy cardiogenic shock in adultsHTG762
Child maltreatment: when to suspect maltreatment in under 18sCG89
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early managementNG255
Suspected sepsis in people aged 16 or over: recognition, assessment and early managementNG253
Suspected sepsis in under 16s: recognition, diagnosis and early managementNG254
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Suspected sepsis in over 16sQS213
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
VA ECMO for severe acute heart failure in adultsHTG764
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrestHTG765
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Atopic eczema in under 12s: diagnosis and managementCG57
Chronic heart failure in adults: diagnosis and managementNG106
Chronic heart failure in adultsQS9
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial managementNG237
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and overTA1093
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessmentHTG759
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Cenobamate for treating focal onset seizures in epilepsyTA753
Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessmentHTG753
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA1077
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Headaches in over 12s: diagnosis and managementCG150
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Falls: assessment and prevention in older people and in people 50 and over at higher riskNG249
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and overHST33
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTA1054
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8

Results per page

  1. 10
  2. 25
  3. 50
  4. All